Shuyi Si

机构：Chinese Academy of Medical Sciences & Peking Union Medical College · ORCID：0000-0003-4422-6848

发表论文 111 篇 · 总被引 4365 次 · h-index 33

代表论文

• A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis (2024 · Acta Pharmacologica Sinica · 被引 92)
• A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α (2020 · EBioMedicine · 被引 53)
• Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasome‐related inflammation and modulating cholesterol transport (2019 · The FASEB Journal · 被引 34)
• The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells (2021 · Acta Pharmaceutica Sinica B · 被引 33)
• Identification of New Antifungal Agents Targeting Chitin Synthesis by a Chemical-Genetic Method (2019 · Molecules · 被引 26)
• Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH/AMPK signaling pathway (2024 · International Journal of Biological Sciences · 被引 21)